- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04243304
Synaptic Density and Progression of Parkinson's Disease.
Longitudinal Measurement of Synaptic Density to Monitor Progression of Parkinson's Disease.
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with PD.
DESIGN: We will include 30 PD patients and 20 healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FE-PE2I PET-MR at baseline and after 2 years.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- UZ Leuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PD diagnosis based on MDS clinical diagnostic criteria for Parkinson's disease
- Less than 5 years disease duration since motor symptom onset according to the patient
- Hoehn-Yahr stage 1 or 2 in medication ON state
- Capacity to understand the informed consent form
Exclusion Criteria:
- Neuropsychiatric diseases other than PD
- Major internal medical diseases
- Relevant abnormalities on MR brain
- History of alcohol or drug abuse
- Contraindications for MR
- Pregnancy
- Previous participation in other research studies involving ionizing radiation with > 1 mSv over past 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PD patients
At baseline and 2-year follow-up
|
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
|
Active Comparator: Healthy controls
At baseline and 2-year follow-up
|
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline differences in synaptic density.
Time Frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
|
Baseline differences (%) in synaptic density between patients and controls.
|
Data analysis wel be done when all subjects have undergone the baseline evaluation.
|
Correlations between clinical scores and synaptic density.
Time Frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Correlations between clinical scores and synaptic density in the patient group.
|
Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Differences in the rate of decline of synaptic density.
Time Frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Differences (%) in the rate of decline of synaptic density between patients and controls.
|
Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Correlations between progression of the clinical scores and decline of synaptic density.
Time Frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Correlations between progression of the clinical scores and decline of synaptic density in the patient group.
|
Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline differences in DAT levels.
Time Frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
|
Baseline differences (%) in DAT levels between patients and controls.
|
Data analysis wel be done when all subjects have undergone the baseline evaluation.
|
Correlations between clinical scores and DAT levels.
Time Frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Correlations between clinical scores and DAT levels in the patient group.
|
Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Differences in the rate of decline of global and DAT levels.
Time Frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Differences (%) in the rate of decline of global and DAT levels between patients and controls.
|
Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Correlations between progression of the clinical scores and decline of DAT levels.
Time Frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Correlations between progression of the clinical scores and decline of DAT levels in the patient group.
|
Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wim Vandenberghe, MD, PhD, UZ Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- s61477
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on 11C-UCB-J PET-CT
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Recruiting
-
Davidzon, Guido, M.D.Stanford UniversitySuspended
-
Davidzon, Guido, M.D.Weston Havens FoundationRecruiting
-
Alkermes, Inc.University Medical Center Groningen; Amsterdam UMC, location VUmc; QPS Netherlands...CompletedHealthy | Alzheimer DiseaseNetherlands
-
Yale UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)RecruitingHealthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV EncephalitisUnited States
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Universitaire Ziekenhuizen KU LeuvenCHDI Foundation, Inc.Not yet recruiting
-
Centre Hospitalier St AnneRoche Pharma AGNot yet recruitingAlzheimer DiseaseFrance
-
Yale UniversityNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...RecruitingHealthy | Bipolar Disorder | Major Depressive DisorderUnited States